- Home
- IVA vs ANAB Comparison
IVA vs ANAB Comparison
Compare IVA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- ANAB
- Stock Information
- Founded
- IVA 2011
- ANAB 2005
- Country
- IVA France
- ANAB United States
- Employees
- IVA N/A
- ANAB N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- IVA Health Care
- ANAB Health Care
- Exchange
- IVA Nasdaq
- ANAB Nasdaq
- Market Cap
- IVA 769.0M
- ANAB 630.2M
- IPO Year
- IVA 2020
- ANAB 2017
- Fundamental
- Price
- IVA $5.61
- ANAB $23.40
- Analyst Decision
- IVA Strong Buy
- ANAB Buy
- Analyst Count
- IVA 6
- ANAB 10
- Target Price
- IVA $15.33
- ANAB $48.00
- AVG Volume (30 Days)
- IVA 74.4K
- ANAB 423.1K
- Earning Date
- IVA 09-26-2025
- ANAB 11-04-2025
- Dividend Yield
- IVA N/A
- ANAB N/A
- EPS Growth
- IVA N/A
- ANAB N/A
- EPS
- IVA N/A
- ANAB N/A
- Revenue
- IVA $14,591,573.00
- ANAB $123,164,000.00
- Revenue This Year
- IVA $80.35
- ANAB $11.22
- Revenue Next Year
- IVA N/A
- ANAB $8.35
- P/E Ratio
- IVA N/A
- ANAB N/A
- Revenue Growth
- IVA N/A
- ANAB 304.17
- 52 Week Low
- IVA $1.53
- ANAB $12.21
- 52 Week High
- IVA $6.50
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- IVA 60.84
- ANAB 61.25
- Support Level
- IVA $5.21
- ANAB $20.61
- Resistance Level
- IVA $5.78
- ANAB $23.64
- Average True Range (ATR)
- IVA 0.38
- ANAB 0.98
- MACD
- IVA -0.02
- ANAB 0.46
- Stochastic Oscillator
- IVA 54.82
- ANAB 94.06
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).